Interaction Checker

Interaksi Akalabrutinib

Akalabrutinib (Calquence) memiliki 86 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 78 mayor, 8 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (78)

  • AmiodaronantiaritmiaMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • AtazanavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • DarunavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Dekslansoprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • DronedaronantiaritmiaMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Esomeprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • EtravirinantiretroviralMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • EverolimusimunosupresanMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Famotidinpenghambat H2Mayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Flukonazolantijamur azolMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • GriseofulvinantijamurMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • IsoniazidantibiotikMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Lansoprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • LenakapavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Naproksen dan esomeprazolOAINSMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Natrium bikarbonatantasidaMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • NefazodonantidepresanMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • NevirapinantiretroviralMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Nizatidinpenghambat H2Mayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Omeprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Pantoprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • PerampanelantikonvulsanMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Posakonazolantijamur azolMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Rabeprazolpenghambat pompa protonMayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Ranitidinpenghambat H2Mayor

    • Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (label Akalabrutinib, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • RifabutinantibiotikMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • RifampisinantibiotikMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • RifapentinantibiotikMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • RitonavirantiretroviralMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • SiklosporinimunosupresanMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • TikagrelorantiplateletMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    • CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (label Akalabrutinib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    • CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (label Akalabrutinib, Interaksi obat)

Interaksi moderat (8)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Gastric Acid Reducing Agents Clinical Effect • Co-administration of CALQUENCE with a proton pump inhibitor, H2-receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations [see Clinical Pharmacology (12.3) ] . (label Akalabrutinib, Interaksi obat)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • KalsiumVitamin dan mineralModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • Kalsium asetatpengikat fosfatModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    • If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). (label Akalabrutinib, Interaksi obat)

Periksa Akalabrutinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.